Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

Abstract Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30–80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinde...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masaaki Nakayama, Noritomo Itami, Hodaka Suzuki, Hiromi Hamada, Ryo Yamamoto, Kazumasa Tsunoda, Naoyuki Osaka, Hirofumi Nakano, Yukio Maruyama, Shigeru Kabayama, Ryoichi Nakazawa, Mariko Miyazaki, Sadayoshi Ito
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fd3e6bee03994dbe9df6e5a963d372cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd3e6bee03994dbe9df6e5a963d372cf
record_format	dspace
spelling	oai:doaj.org-article:fd3e6bee03994dbe9df6e5a963d372cf2021-12-02T15:08:40ZNovel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study10.1038/s41598-017-18537-x2045-2322https://doaj.org/article/fd3e6bee03994dbe9df6e5a963d372cf2018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-18537-xhttps://doaj.org/toc/2045-2322Abstract Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30–80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n = 161) group or the conventional HD (C-HD: n = 148) group, and received the respective HD treatments during the study. The primary endpoint was a composite of all-cause mortality and development of non-lethal cardio-cerebrovascular events (cardiac disease, apoplexy, and leg amputation due to peripheral artery disease). During the 3.28-year mean observation period, there were no differences in dialysis parameters between the two groups; however, post-dialysis hypertension was ameliorated with significant reductions in antihypertensive agents in the E-HD patients. There were 91 events (50 in the C-HD group and 41 in the E-HD group). Multivariate analysis of the Cox proportional hazards model revealed E-HD as an independent significant factor for the primary endpoint (hazard ratio 0.59; [95% confidence interval: 0.38–0.92]) after adjusting for confounding factors (age, cardiovascular disease history, serum albumin, and C-reactive protein). HD applying an H2-dissolved HD solution could improve the prognosis of chronic HD patients.Masaaki NakayamaNoritomo ItamiHodaka SuzukiHiromi HamadaRyo YamamotoKazumasa TsunodaNaoyuki OsakaHirofumi NakanoYukio MaruyamaShigeru KabayamaRyoichi NakazawaMariko MiyazakiSadayoshi ItoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Masaaki Nakayama Noritomo Itami Hodaka Suzuki Hiromi Hamada Ryo Yamamoto Kazumasa Tsunoda Naoyuki Osaka Hirofumi Nakano Yukio Maruyama Shigeru Kabayama Ryoichi Nakazawa Mariko Miyazaki Sadayoshi Ito Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
description	Abstract Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30–80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n = 161) group or the conventional HD (C-HD: n = 148) group, and received the respective HD treatments during the study. The primary endpoint was a composite of all-cause mortality and development of non-lethal cardio-cerebrovascular events (cardiac disease, apoplexy, and leg amputation due to peripheral artery disease). During the 3.28-year mean observation period, there were no differences in dialysis parameters between the two groups; however, post-dialysis hypertension was ameliorated with significant reductions in antihypertensive agents in the E-HD patients. There were 91 events (50 in the C-HD group and 41 in the E-HD group). Multivariate analysis of the Cox proportional hazards model revealed E-HD as an independent significant factor for the primary endpoint (hazard ratio 0.59; [95% confidence interval: 0.38–0.92]) after adjusting for confounding factors (age, cardiovascular disease history, serum albumin, and C-reactive protein). HD applying an H2-dissolved HD solution could improve the prognosis of chronic HD patients.
format	article
author	Masaaki Nakayama Noritomo Itami Hodaka Suzuki Hiromi Hamada Ryo Yamamoto Kazumasa Tsunoda Naoyuki Osaka Hirofumi Nakano Yukio Maruyama Shigeru Kabayama Ryoichi Nakazawa Mariko Miyazaki Sadayoshi Ito
author_facet	Masaaki Nakayama Noritomo Itami Hodaka Suzuki Hiromi Hamada Ryo Yamamoto Kazumasa Tsunoda Naoyuki Osaka Hirofumi Nakano Yukio Maruyama Shigeru Kabayama Ryoichi Nakazawa Mariko Miyazaki Sadayoshi Ito
author_sort	Masaaki Nakayama
title	Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
title_short	Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
title_full	Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
title_fullStr	Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
title_full_unstemmed	Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study
title_sort	novel haemodialysis (hd) treatment employing molecular hydrogen (h2)-enriched dialysis solution improves prognosis of chronic dialysis patients: a prospective observational study
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/fd3e6bee03994dbe9df6e5a963d372cf
work_keys_str_mv	AT masaakinakayama novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT noritomoitami novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT hodakasuzuki novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT hiromihamada novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT ryoyamamoto novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT kazumasatsunoda novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT naoyukiosaka novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT hirofuminakano novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT yukiomaruyama novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT shigerukabayama novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT ryoichinakazawa novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT marikomiyazaki novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy AT sadayoshiito novelhaemodialysishdtreatmentemployingmolecularhydrogenh2enricheddialysissolutionimprovesprognosisofchronicdialysispatientsaprospectiveobservationalstudy
_version_	1718388101237178368

Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

Ejemplares similares